IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma
- PMID: 37883983
- DOI: 10.1016/S0140-6736(23)01962-1
IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma
Conflict of interest statement
AV reports personal fees from Roche, who sponsored the IMbrave050 trial, and Bayer, Sanofi, BMS, Lilly, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, Terumo, GSK, Imaging Equipment, and Daichi-Sankyo outside the scope of this Comment. TM reports personal fees from Adaptimmune, AstraZeneca, BMS, Boston Scientific, Eisai, Ipsen, and Roche outside the scope of this Comment. AS reports personal fees from Servier, Ipsen, Lilly, AstraZeneca, and MSD; and travel support from Ipsen, Servier, PierreFabre, MSD, Adboard, Eisai, and MSD outside the scope of this Comment.
Comment on
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical